WITHDRAWN: Hidrosmin Attenuates Inflammatory Response Induced by IL1β by Suppressing the Activation of NF-κB Involving Nrf2/HO1 Pathway in Human Osteoarthritis Chondrocytes

Title:WITHDRAWN: Hidrosmin Attenuates Inflammatory Response Induced by IL1β by Suppressing the Activation of NF-κB Involving Nrf2/HO1 Pathway in Human Osteoarthritis Chondrocytes

Volume: 23

Author(s): Yu Mingchuan, Chen Xiang, Xiao Yuhong, Ye Jing, Liu Yu, Wang Di, Xiao Haili and Luo Jun*

Affiliation:

• Department of Rehabilitation Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang city, Jiangxi province, China, 33000

Abstract: Since the authors are not responding to the editor’s requests to fulfill the editorial requirement, therefore, the article has been withdrawn from the journal "Current Cancer Drug Targets"

Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.

The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php.

BENTHAM SCIENCE DISCLAIMER:

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.

Cite this article as:

Mingchuan Yu, Xiang Chen, Yuhong Xiao, Jing Ye, Yu Liu, Di Wang, Haili Xiao and Jun Luo*, WITHDRAWN: Hidrosmin Attenuates Inflammatory Response Induced by IL1β by Suppressing the Activation of NF-κB Involving Nrf2/HO1 Pathway in Human Osteoarthritis Chondrocytes, Current Cancer Drug Targets 2023; 23 () . https://dx.doi.org/10.2174/1568009623666230209120520